COVID Shot: FDA Bait & Switch?

Date:  August 30, 2021
Host:  Jim Schneider
​Guest:  Mat Staver
MP3 ​​​| Order

On August 23, 2021, the U.S. Food and Drug Administration issued a press release in which they announced they had approved the first COVID-19 vaccine.  Their press release said the vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty for the prevention of COVID-19 disease in individuals 16 years of age and older.  Mat Staver, the founder and chairman of Liberty Counsel, believes this is nothing more than bait and switch.

Mat explained what’s taking place here in five steps:

#1—All existing Pfizer vials remain under the Federal Emergency Use Authorization (EUA).  This means people still have the option to except or refuse them.  

#2—The third are booster shots Pfizer has that are identical to the above and remains under EUA with limited use to people in certain categories.

#3—BioNTech received FDA approval for people ages 16 and older under the name, Comirnaty.  However, there is no Comirnaty dose available in the U.S.

#4—There is currently no FDA approved COVID-19 injection available anywhere in the U.S.  Every COVID-19 shot in America remains under EUA law and people have the right to accept or refuse them.

#5—Even when FDA approval of COVID-19 shots does become available, individuals are still protected by federal law (and many state laws as well) from being forced to get the vaccines based upon their sincere religious beliefs or conscience objections.   

Jim summarized by noting that what we have here are two legally distinct but otherwise identical products.  Mat agreed and added that what we have here is one vaccine called Pfizer (currently in existence in the U.S. under EUA) and the other is called Comirnaty (currently not in the U.S. so there is no availability of this as an approved FDA COVID-19 shot).    

Get informed on the latest vaccine news, and hear what listeners had to say as well, when you review this vital edition of Crosstalk.

More Information

Leave a Reply